---
canonical_name: Phellodendron amurense
alternate_names: Amur Cork Tree, Huang Bai, Huang Bo, Guan Huang Bai, Phellodendri amurensis Cortex, Cortex Phellodendri, Nexrutine, Phellodendron
canonical_topic: Phellodendron amurense for Health & Longevity
short_topic_lc: phellodendron_amurense
creation_date: 2026-1017-2309
creator_ai_fullname: Gemini 4 Argon
---
# Phellodendron amurense for Health & Longevity  
<section id="top" markdown="1"></section>  
Evidence Review created on 10/17/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Gemini 4 Argon  
  
**Also known as:** Amur Cork Tree, Huang Bai, Huang Bo, Guan Huang Bai, Phellodendri amurensis Cortex, Cortex Phellodendri, Nexrutine, Phellodendron  
  
  
## Motivation  
  
<!-- This Motivation section was written only after the rest of the document was completed so that it reflects the full scope of the review. -->  
  
*Phellodendron amurense* (also known as the Amur cork tree or *Guan Huang Bai*) is a deciduous tree native to northeastern Asia whose dried inner bark is used in botanical supplements. Proactive adults interested in health and longevity encounter this bark in standalone extracts and multi-herb blends positioned for metabolic health, stress regulation, and joint comfort. Its primary bitter plant compounds interact with cellular energy sensors and inflammatory signaling pathways in laboratory models.  
  
Practitioners of East Asian herbal medicine have prepared brewed bark teas and topical washes from the inner bark for centuries to address heat, dampness, and skin irritation. Over the past two decades, supplement manufacturers have developed concentrated bark extracts—both alone and paired with magnolia bark or citrus peel—that have been studied in human clinical trials for stress-related eating, knee discomfort, and prostate care.  
  
This review examines the human clinical studies, biological mechanisms, safety profile, medication interactions, and practical protocols for *Phellodendron amurense* preparations to clarify how the available evidence applies to long-term health optimization.  
  
**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**  
  
  
## Recommended Reading  
  
<!-- Recommended Reading search log: Performed real-time web and on-site searches across priority platforms (d-browser / d-fetch / d-proxy-1): Rhonda Patrick (https://www.foundmyfitness.com/search?q=Phellodendron -> 0 results), Peter Attia (https://peterattiamd.com/?s=Phellodendron -> Nothing Found), Andrew Huberman (https://www.hubermanlab.com/search?q=Phellodendron -> No results found), Chris Kresser (https://chriskresser.com/?s=Phellodendron -> No search results), Life Extension Magazine (https://www.lifeextension.com/magazine/2021/4/boost-dopamine-levels -> verified via d-fetch), Lifespan.io (https://lifespan.io/topic/berberine-benefits-side-effects/ -> verified via d-browser). Selected 2 qualifying articles from priority platforms and 3 PubMed narrative reviews from distinct research groups. -->  
  
The following articles and narrative reviews provide accessible overviews and detailed scientific background on *Phellodendron amurense*, its bioactive constituents, and its clinical applications.  
  
- [Phellodendron Supports Healthy Dopamine Levels](https://www.lifeextension.com/magazine/2021/4/boost-dopamine-levels) - Stuart Nadel  
  
  Explores how *Phellodendron amurense* bark extract inhibits monoamine oxidase B (MAO-B, a brain enzyme that breaks down dopamine) to support cellular neuroprotection and healthy dopamine signaling during aging.  
  
- [Berberine: Benefits, Uses and Side Effects](https://lifespan.io/topic/berberine-benefits-side-effects/) - Steve Hill  
  
  Examines berberine—the principal active alkaloid in *Phellodendron amurense* bark—and its activation of adenosine monophosphate-activated protein kinase (AMPK, a master cellular energy sensor) for metabolic and longevity optimization.  
  
- [An Updated and Comprehensive Review of Phellodendri amurensis Cortex: Ethnobotany, Geographical Distribution, Phytochemistry, Quality Control, and Pharmacology.](https://pubmed.ncbi.nlm.nih.gov/42075995/) - Li et al., 2026  
  
  Synthesizes approximately 170 phytochemical constituents isolated from *Phellodendron amurense* bark alongside botanical authentication standards, pharmacological mechanisms, and preclinical toxicology findings.  
  
- [Phellodendri Cortex: A Phytochemical, Pharmacological, and Pharmacokinetic Review.](https://pubmed.ncbi.nlm.nih.gov/31057654/) - Sun et al., 2019  
  
  Compares the chemical profiles, intestinal absorption, tissue distribution, and cytochrome P450 (CYP450, a family of liver enzymes that metabolize medications) interactions of *Phellodendron amurense* and *Phellodendron chinense*.  
  
- [Extracting the Benefit of Nexrutine(®) for Cancer Prevention.](https://pubmed.ncbi.nlm.nih.gov/26539341/) - Hussain et al., 2015  
  
  Reviews the molecular signaling targets, preclinical tumor-prevention data, and early human clinical testing of the proprietary *Phellodendron amurense* bark extract Nexrutine.  
  
Note: Priority experts Rhonda Patrick, Peter Attia, Andrew Huberman, and Chris Kresser were searched directly, but none have published articles or podcast episodes evaluating *Phellodendron amurense*.  
  
  
## Grokipedia  
  
<!-- Grokipedia lookup: Searched https://grokipedia.com/search?q=Phellodendron+amurense via d-browser; retrieved and verified primary dedicated article at https://grokipedia.com/page/Phellodendron_amurense via d-browser. -->  
  
- [Phellodendron amurense](https://grokipedia.com/page/Phellodendron_amurense)  
  
  Provides a comprehensive reference overview of the botany, traditional East Asian uses, phytochemical profile, and modern clinical research surrounding *Phellodendron amurense* bark.  
  
  
## Examine  
  
<!-- Examine lookup: Searched https://examine.com/search/?q=Phellodendron+amurense; d-browser hit Vercel Security Checkpoint, d-fetch returned HTTP 429, and d-proxy-1 retrieved and verified the primary dedicated page at https://examine.com/supplements/phellodendron-amurense/. -->  
  
- [Phellodendron amurense benefits, dosage, and side effects](https://examine.com/supplements/phellodendron-amurense/)  
  
  Summarizes the human clinical trials of *Phellodendron amurense* combination supplements for stress, weight management, and joint health, alongside dosing and safety considerations.  
  
  
## ConsumerLab  
  
<!-- ConsumerLab lookup: Searched https://www.consumerlab.com/search/?q=Phellodendron+amurense across d-browser, d-fetch, d-proxy-1, and d-proxy-2; d-browser returned search results confirming no dedicated primary ConsumerLab article or product review for Phellodendron amurense exists. -->  
  
No dedicated ConsumerLab article for *Phellodendron amurense* was found.  
  
  
## Systematic Reviews  
  
The following systematic reviews and meta-analyses evaluate topical or multi-herb preparations containing *Phellodendron* bark, preclinical cachexia models, or its principal isolated compound berberine.  
  
- [The effect of externally applied traditional Chinese medicine in diabetic foot: A systematic review and meta-analysis of 34 RCTs.](https://pubmed.ncbi.nlm.nih.gov/37499379/) - Yang et al., 2023  
  
  Pools 34 randomized controlled trials (RCTs, studies randomly assigning participants to treatment or control), including nine testing topical *Cortex Phellodendri* liquid for ulcers.  
  
- [Erxian decoction, a Chinese herbal formula, for menopausal syndrome: An updated systematic review.](https://pubmed.ncbi.nlm.nih.gov/30658181/) - Wang et al., 2019  
  
  Evaluates 16 RCTs of a traditional six-herb formula containing *Cortex Phellodendri* for reducing menopausal hot flashes and symptom severity scores.  
  
- [A systematic review of herbal medicines for the treatment of cancer cachexia in animal models.](https://pubmed.ncbi.nlm.nih.gov/30614226/) - Park et al., 2019  
  
  Reviews rodent studies of cancer cachexia (severe disease-related muscle wasting), finding *Phellodendri Cortex* preserves muscle via the ubiquitin-proteasome (cellular protein-degradation) pathway.  
  
- [Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.](https://pubmed.ncbi.nlm.nih.gov/25498346/) - Lan et al., 2015  
  
  Pools 27 RCTs (2,569 patients) of purified berberine, the primary active compound in *Phellodendron* bark, demonstrating improvements in blood glucose, lipids, and blood pressure.  
  
No systematic review or meta-analysis on PubMed evaluates oral *Phellodendron amurense* bark monotherapy. Consequently, proposed standalone benefits—including stress and cortisol modulation, osteoarthritis pain relief, weight management, C-reactive protein (CRP, a blood protein marker of systemic inflammation) and erythrocyte sedimentation rate (ESR, a red-cell settling inflammation marker) reduction, and benign prostatic hyperplasia (BPH, non-cancerous prostate enlargement) or prostate-specific antigen (PSA, a prostate protein marker) support—and principal risks—including CYP450 drug interactions, corrected QT interval (QTc, a heart-rhythm recharging measurement on an electrocardiogram) prolongation, neonatal hyperbilirubinemia (excess bilirubin in newborn blood causing jaundice) and kernicterus (severe bilirubin-induced brain damage) in glucose-6-phosphate dehydrogenase (G6PD, an enzyme protecting red blood cells)-deficient infants, high-dose kidney or liver injury, and World Anti-Doping Agency (WADA, international sports anti-doping regulator) violations—have no direct systematic review coverage.  
  
  
## Mechanism of Action  
  
*Phellodendron amurense* inner bark contains roughly 170 phytochemicals, led by isoquinoline alkaloids—chiefly berberine (0.6%–4.5% of dry weight), palmatine (0.3%–2.0%), and phellodendrine—and bitter triterpenes called limonoids, primarily obacunone and limonin ([Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/); [Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)). Berberine and palmatine mildly inhibit mitochondrial complex I, raising the ratio of adenosine monophosphate to adenosine triphosphate (ATP, the primary cellular energy molecule) and activating AMPK to boost glucose uptake while stabilizing hepatic low-density lipoprotein receptor (LDLR, a liver receptor that clears blood cholesterol) messenger ribonucleic acid (mRNA, genetic templates for protein synthesis).  
  
Because protoberberine alkaloids undergo intestinal extrusion by P-glycoprotein (P-gp, a cell-membrane pump that exports drugs) and extensive first-pass metabolism, oral bioavailability is below 1%, with a human elimination half-life of 3 to 5 hours and selective accumulation in liver, kidney, and intestinal tissues ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)). Competing mechanistic hypotheses therefore debate whether systemic effects arise from direct tissue signaling or gut microbiome remodeling. Preclinically, Nexrutine and limonoids inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB, a master switch driving inflammatory genes), signal transducer and activator of transcription 3 (STAT3, a protein regulating cell survival and inflammation), and cyclooxygenase-2 (COX-2, an enzyme producing inflammatory prostaglandins) ([Hussain et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26539341/)). Systemically, berberine inhibits cytochrome P450 2D6 (CYP2D6, a liver enzyme metabolizing beta-blockers and antidepressants), cytochrome P450 2C9 (CYP2C9, a liver enzyme clearing warfarin and anti-inflammatories), and cytochrome P450 3A4 (CYP3A4, the primary enzyme clearing prescription drugs) ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)).  
  
  
## Historical Context & Evolution  
  
For more than two millennia, practitioners of traditional Chinese, Korean, and Japanese medicine have used the dried inner bark of *Phellodendron amurense*—known as *Guan Huang Bai*—as a bitter, cooling remedy to clear damp-heat in dysentery, jaundice, urinary tract inflammation, and skin sores ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/); [Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)). Traditional pharmacopeias treated northern *Phellodendron amurense* and southern *Phellodendron chinense* (*Chuan Huang Bai*) interchangeably until quantitative chromatography revealed that *Phellodendron amurense* contains lower berberine but higher palmatine and limonoid levels, prompting their separation into distinct monographs ([Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)).  
  
Modern interest in *Phellodendron amurense* for health optimization emerged in the early 2000s through three commercial formulations. First, oncology researchers investigated **Nexrutine**, a fractionated bark extract, finding that it suppressed COX-2 and NF-κB signaling and slowed prostate tumor progression in TRAMP (transgenic adenocarcinoma of the mouse prostate, a genetically engineered prostate-cancer mouse) models ([Hussain et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26539341/); [Patel et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31856170/)), prompting a human phase I/II tolerance trial ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)). Second, proprietary manufacturer Next Pharmaceuticals introduced **Relora** (*Magnolia officinalis* and *Phellodendron amurense* barks) and **NP 06-1** (*Phellodendron amurense* bark and *Citrus sinensis* peel), funding and co-authoring small randomized trials for stress, cortisol, knee osteoarthritis, and cardiometabolic markers ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/); [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/); [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)). While longevity enthusiasts initially grouped *Phellodendron* with berberine, subsequent scrutiny has highlighted the lack of standalone trials and industry sponsorship.  
  
  
## Expected Benefits  
  
<!-- Expected Benefits search log: Searched PubMed, ClinicalTrials.gov, Examine, and Google Scholar for all human clinical trials, systematic reviews, observational studies, and preclinical models of Phellodendron amurense, Guan Huang Bai, Nexrutine, Relora, NP 06-1, and Phellodendron Bawei tablets, explicitly including trials showing null or conflicting outcomes (Garrison & Chambliss, 2006; Kalman et al., 2008; Oben et al., 2008; Oben et al., 2009; Talbott et al., 2013; Liu et al., 2020). -->  
  
### High 🟩 🟩 🟩  
  
No benefit reaches High: no randomized controlled trials from independent research groups have evaluated isolated oral *Phellodendron amurense* monotherapy on validated human clinical endpoints.  
  
### Medium 🟩 🟩  
  
No benefit reaches Medium: the only human trial of isolated oral *Phellodendron amurense* bark extract is an uncontrolled single-arm pilot study, while all randomized controlled trials tested multi-ingredient blends, purified berberine, or topical preparations.  
  
### Low 🟩  
  
#### Cardiometabolic Lipid, Blood Pressure & Glucose Regulation ⚠️ Conflicted  
  
Tested indirectly in blends ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/); [Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/)) or as purified berberine ([Lan et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25498346/)). Next Pharmaceuticals-funded NP 06-1 improved lipids, blood pressure, and overweight glucose, and a crape-myrtle blend lowered post-load glucose, whereas normal-weight glucose was unchanged. Overall, standalone metabolic efficacy remains unproven.  
  
**Magnitude:** In [Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/) (45 completers), 8-week overweight fasting glucose decreased by 19.6% vs. no significant change on placebo (p < 0.001 between groups) and low-density lipoprotein cholesterol (LDL-C, atherogenic blood cholesterol) decreased 3.1-fold more than placebo (-44.6% vs. -14.2%, p < 0.01 between groups); in [Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/) (10 men), post-dextrose serum glucose was lower than placebo (p = 0.01); in [Lan et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25498346/), purified berberine reduced hemoglobin A1c (HbA1c, 3-month average blood glucose) by 0.72% more than control (95% confidence interval (CI, statistical range of plausible true effect) -0.97% to -0.47%).  
  
#### Systemic Inflammation (C-Reactive Protein) ⚠️ Conflicted  
  
Tested indirectly as the Next Pharmaceuticals-sponsored *Phellodendron amurense* and *Citrus sinensis* blend NP 06-1 in an 8-week knee osteoarthritis RCT ([Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)). Serum CRP fell significantly in overweight adults, whereas normal-weight CRP and ESR were unchanged. Overall, systemic anti-inflammatory activity is inconsistent and unconfirmed for standalone bark.  
  
**Magnitude:** In [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/) (45 completers), serum CRP in overweight osteoarthritis patients changed by -0.62 ± 0.2 mg/L (-49%) on NP 06-1 vs. placebo (p < 0.001 between groups), whereas normal-weight CRP and ESR in both cohorts showed no significant difference from placebo.  
  
#### Stress, Anxiety & Cortisol Modulation ⚠️ Conflicted  
  
Tested indirectly in Next Pharmaceuticals-sponsored RCTs of the *Magnolia officinalis* and *Phellodendron amurense* blend Relora. [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/) lowered cortisol and stress and [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/) reduced state anxiety (not cortisol or trait anxiety), whereas [Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/) found null overall effects. Overall, stress benefits remain mixed.  
  
**Magnitude:** In [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/) (56 adults), salivary cortisol was 18% lower and perceived stress 11% lower than placebo at 4 weeks (p < 0.05); in [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/) (26 completers), 6-week Spielberger state anxiety score decreased 6.7 points more on Relora than placebo (-14.3 ± 12.1 vs. -7.6 ± 9.8, p = 0.045), while salivary cortisol and trait anxiety did not differ significantly from placebo; in [Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/) (28 completers), between-group cortisol changes were non-significant (p < 0.15 average, p = 0.06 evening).  
  
#### Osteoarthritis Joint Pain & Mobility  
  
Tested indirectly with *Citrus sinensis* peel extract (NP 06-1, 1,480 mg/day) in a Next Pharmaceuticals-sponsored 8-week RCT of 80 knee osteoarthritis patients ([Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)). Treatment significantly improved Lequesne Algofunctional Index pain and mobility scores versus placebo in both weight cohorts, though 43.8% attrition limits certainty.  
  
**Magnitude:** At 8 weeks in [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/), mean Lequesne Algofunctional Index score was 5.5 points lower than placebo in overweight patients (6.3 ± 2.3 vs. 11.8 ± 1.5, p < 0.0001) and 2.2 points lower than placebo in normal-weight patients (7.7 ± 1.4 vs. 9.9 ± 0.9, p < 0.0001).  
  
#### Body Weight & Stress-Related Weight Management ⚠️ Conflicted  
  
Tested indirectly in Next Pharmaceuticals-sponsored blends with *Citrus sinensis* ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/)) or *Magnolia officinalis* ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/); [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/); [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)). NP 06-1 reduced weight and one Relora trial prevented gain, whereas two Relora RCTs showed no effect. Overall, weight benefits remain unproven.  
  
**Magnitude:** In [Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/) (45 completers), 8-week overweight weight loss was 3.1 kg (6.7 lb) greater on NP 06-1 than placebo (-4.2 kg [-9.2 lb] vs. -1.1 kg [-2.5 lb], 3.7-fold greater, p < 0.001 between groups); in [Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/), 6-week weight change was 1.45 kg less than placebo (+0.05 kg vs. +1.50 kg, p < 0.05); in [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/) and [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/), weight did not differ significantly between groups (exact figures not reported).  
  
#### Prostate-Specific Antigen & Lower Urinary Tract Symptoms ⭕️ Not Central to Health & Longevity  
  
Evaluated in an uncontrolled trial of oral Nexrutine (1,500 mg/day) in 21 prostate cancer patients undergoing surgery or radiation ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)) and a 6-month RCT of multi-herb *Phellodendron* Bawei tablets in BPH ([Gong et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34532267/)). Bears on localized prostatic disease and urinary symptoms rather than systemic longevity.  
  
**Magnitude:** In [Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/), serum PSA declined in 81% (17/21) of patients receiving Nexrutine plus radiation or surgery (no control group); in [Gong et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34532267/) (120 randomized, 105 completers), adding *Phellodendron* Bawei tablets to tamsulosin plus finasteride for 6 months improved International Prostate Symptom Score (IPSS, a validated urinary symptom questionnaire) storage subscores (p = 0.027), Athens Insomnia Scale sleep quality (p < 0.001), and medication compliance (p = 0.003) vs. placebo plus tamsulosin and finasteride (exact score figures not reported in abstract).  
  
#### Topical Ulcer, Phlebitis & Acne Resolution ⭕️ Not Central to Health & Longevity  
  
Tested indirectly via topical application rather than oral use for infusion phlebitis (vein inflammation from intravenous lines) ([Wan, 2018](https://pubmed.ncbi.nlm.nih.gov/29735457/)), mild-to-moderate acne ([Zhang et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29808477/)), and diabetic foot ulcers ([Yang et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37499379/); [Liu et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32817595/)). Bears on localized cutaneous wound and skin healing rather than systemic healthspan.  
  
**Magnitude:** In [Yang et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37499379/), topical compound *Cortex Phellodendri* liquid increased diabetic foot ulcer healing with a risk ratio (RR, probability ratio of an outcome between treatment and control groups) of 1.84 (95% CI 1.56 to 2.17); in [Liu et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32817595/) (720 patients), 4-week ulcer area reduction and total effective rate exceeded Kangfuxin control (p < 0.05); in [Wan, 2018](https://pubmed.ncbi.nlm.nih.gov/29735457/) (600 patients), phlebitis resolution exceeded magnesium sulfate compress (p < 0.05); in [Zhang et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29808477/), acne efficacy exceeded control.  
  
### Speculative 🟨  
  
#### Tumor Growth Suppression & Chemosensitization  
  
In prostate-tumor mice and cancer cells, Nexrutine suppresses tumor progression and restores docetaxel sensitivity via NF-κB inhibition ([Patel et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31856170/); [Zhang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28485511/)). No controlled human trials exist; evidence is preclinical only.  
  
#### Skeletal Muscle Preservation in Cachexia  
  
In prostate-tumor mice, Nexrutine preserves gastrocnemius muscle mass and lowers proteolysis-inducing factor ([Patel et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31456341/)), while *Phellodendri Cortex* modulates ubiquitin-proteasome wasting ([Park et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30614226/)). No controlled human studies exist; evidence is animal only.  
  
#### Neuroprotection & Monoamine Oxidase B Inhibition  
  
*Phellodendron amurense* extracts protect cultured neuronal cells against beta-amyloid toxicity and potently inhibit recombinant human MAO-B ([Xian et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23123224/); [Zarmouh et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27341283/)). No controlled human studies exist; this remains mechanistic only.  
  
  
## Benefit-Modifying Factors  
  
- **Genetic polymorphisms:** Variants in *ABCB1* (encoding the intestinal efflux pump P-gp) and *SLC22A1* (encoding organic cation transporter 1, which mediates liver drug uptake) alter intestinal absorption and hepatic extraction of protoberberine alkaloids ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)), shifting systemic vs. gut-mediated responses.  
- **Baseline biomarker levels:** In the 8-week NP 06-1 trials ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/); [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)), fasting glucose and serum CRP reductions occurred exclusively in participants with elevated baseline body mass index (BMI, weight-to-height ratio in kg/m²) and higher baseline inflammation.  
- **Sex-based differences:** Stress-eating trials of Relora enrolled exclusively premenopausal women ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/); [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/)), whereas mixed-sex ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)) and male-only ([Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/)) studies have not performed sex-stratified efficacy comparisons.  
- **Pre-existing health conditions:** Individuals with insulin resistance, dyslipidemia, or knee osteoarthritis show larger biomarker shifts in combination trials ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/); [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)) than normoglycemic, normal-weight adults.  
- **Age-related considerations:** Older adults (ages 50 to 80) studied in osteoarthritis ([Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)) and prostate trials ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/); [Gong et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34532267/)) experience age-related declines in gut motility and hepatic clearance that may alter alkaloid exposure.  
  
  
## Potential Risks & Side Effects  
  
<!-- Potential Risks & Side Effects search log: Searched PubMed, ClinicalTrials.gov, Examine, and pharmacological/toxicological reviews (Sun et al., 2019; Fan et al., 2019; Alam et al., 2021; Sakamoto et al., 2025; Li et al., 2026) and clinical trials (Wu et al., 2005; Guo et al., 2012; Swanson et al., 2015; Talbott et al., 2013; Oben et al., 2009; Gong et al., 2021) for adverse events, drug interactions, organ toxicity, and studies finding no excess risk. -->  
  
### High 🟥 🟥 🟥  
  
No risk reaches High: no large randomized controlled trials or replicated human safety studies from independent research groups have evaluated isolated oral *Phellodendron amurense* monotherapy.  
  
### Medium 🟥 🟥  
  
No risk reaches Medium: human safety data for isolated oral *Phellodendron amurense* are limited to a single 21-patient uncontrolled study, while controlled trials tested multi-ingredient blends or isolated constituent alkaloids.  
  
### Low 🟥  
  
#### Cytochrome P450 & P-Glycoprotein Drug Interaction Toxicity  
  
Indirect evidence from human crossover pharmacokinetic trials of its principal alkaloid berberine demonstrates potent inhibition of hepatic CYP2D6, CYP2C9, CYP3A4, and intestinal P-gp ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)). This impairs drug clearance and elevates blood concentrations of narrow-therapeutic-index medications such as cyclosporine A in transplant recipients ([Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/)).  
  
**Magnitude:** In [Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/) (17 men), berberine (900 mg/day) increased the CYP2D6 dextromethorphan/dextrorphan ratio by 0.91 over placebo (1.02 ± 1.25 vs. 0.11 ± 0.13, p < 0.01), increased the CYP2C9 losartan ratio by 1.01 over placebo (2.05 ± 1.09 vs. 1.04 ± 0.52, p < 0.01), and raised CYP3A4 midazolam area under the curve (AUC, total systemic drug exposure over time) by 40% vs. placebo (p < 0.05); in [Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/) (104 renal transplant patients), final cyclosporine A trough levels were 29.3% higher with berberine than control (p < 0.05) and oral clearance decreased by 40.4% (p < 0.05).  
  
#### Gastrointestinal Distress (Nausea, Diarrhea, Constipation & Heartburn) ⚠️ Conflicted  
  
Uncontrolled Nexrutine dosing ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)) and berberine RCTs ([Lan et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25498346/)) report mild digestive complaints, whereas combination RCTs ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/); [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/); [Gong et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34532267/)) found no excess risk over placebo. Overall, mild digestive upset occurs mainly at higher alkaloid doses.  
  
**Magnitude:** Grade 1–2 diarrhea or constipation occurred in 9.5% (2/21) of Nexrutine patients in [Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/) (no control group); adverse-event withdrawal (heartburn or fatigue) was 4.7% higher on Relora than placebo (10.0% [2/20] vs. 5.3% [1/19]) in [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/); nausea dropout was 2.5% lower on NP 06-1 than placebo (2.5% [1/40] vs. 5.0% [2/40]) in [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/); and adverse events were 0% vs. 0% in [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/).  
  
#### Mild QTc Interval Prolongation & Electrolyte Shifts  
  
In the single-arm trial of oral Nexrutine (1,500 mg/day) in 21 prostate cancer patients, [Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/) documented transient Grade 1 QTc prolongation, mild leukopenia (low white blood cells), and one Grade 3 hypokalemia (low blood potassium) episode. Causality remains uncertain without a control group.  
  
**Magnitude:** Grade 1 QTc prolongation occurred in 14.3% (3/21) of patients and transient Grade 3 hypokalemia in 4.8% (1/21) of patients in [Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/) (no control group).  
  
#### Neonatal Hyperbilirubinemia & Kernicterus Risk  
  
Indirect clinical and pharmacological reviews of berberine-containing herbs show that berberine displaces unconjugated bilirubin from albumin and inhibits hepatic bilirubin clearance ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/); [Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)). This can precipitate severe neonatal hyperbilirubinemia and kernicterus in exposed fetuses, neonates, and G6PD-deficient infants.  
  
**Magnitude:** Not quantified in available studies. No controlled clinical study has measured the incidence of hyperbilirubinemia or kernicterus specifically following *Phellodendron amurense* administration, as available evidence derives from case reports and bilirubin-displacement studies of berberine-containing herbs.  
  
### Speculative 🟨  
  
#### High-Dose Renal Tubular Degeneration & Limonin Hepatotoxicity  
  
In rats, high-dose Nexrutine (750 mg/kg/day) caused mild renal tubular degeneration ([Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)), and limonin induced rodent hepatorenal injury ([Fan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31614806/)). No controlled human data exist; this remains preclinical only.  
  
#### Unintentional Anti-Doping Violation (Higenamine Formation)  
  
In mice and human liver microsomes, coclaurine in *Phellodendron* bark converts into the WADA-banned beta-2 agonist (bronchodilator and stimulant class) higenamine ([Sakamoto et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40751788/)). No controlled human trials exist; evidence is mechanistic only.  
  
  
## Risk-Modifying Factors  
  
- **Genetic polymorphisms:** Inherited intermediate or poor metabolizer variants in *CYP2D6* or *CYP2C9* compound the enzyme inhibition caused by berberine ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)), while G6PD-deficiency variants heighten hemolytic and bilirubin toxicity risks ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)).  
- **Baseline biomarker levels:** Prolonged baseline QTc, low serum potassium (< 3.8 mmol/L), or elevated liver enzymes increase susceptibility to cardiac, electrolyte, and hepatorenal shifts ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/); [Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)).  
- **Sex-based differences:** Women have longer baseline QTc intervals than men (increasing arrhythmia susceptibility with QTc-prolonging agents), and pregnancy or lactation introduces fetal and neonatal bilirubin-displacement hazards ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)).  
- **Pre-existing health conditions:** Chronic kidney disease, hepatic impairment, cardiac conduction disorders, or polypharmacy with narrow-therapeutic-index drugs substantially elevate the risk of drug accumulation and organ toxicity ([Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/); [Fan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31614806/)).  
- **Age-related considerations:** Older adults frequently take multiple CYP2D6, CYP2C9, or CYP3A4 substrate medications and have lower baseline renal filtration, amplifying pharmacokinetic interaction hazards ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)).  
  
  
## Key Interactions & Contraindications  
  
<!-- Key Interactions & Contraindications search log: Performed dedicated PubMed search for Phellodendron amurense, Cortex Phellodendri, Nexrutine, Relora, and berberine with "drug interaction" OR "pharmacokinetics" in humans; retrieved and verified Wu et al., 2005 (PMID 16133554), Guo et al., 2012 (PMID 21870106), Sun et al., 2019 (PMID 31057654), Sakamoto et al., 2025 (PMID 40751788), and Li et al., 2026 (PMID 42075995). -->  
  
- **Calcineurin inhibitor immunosuppressants (cyclosporine A, tacrolimus):** Avoid or monitor closely. Constituent berberine inhibits CYP3A4 and P-gp, raising cyclosporine A trough concentrations by 29.3% over control and cutting clearance by 40.4% ([Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/)), risking nephrotoxicity; requires therapeutic drug monitoring and dose reduction.  
- **Prescription CYP2D6 substrates (metoprolol, carvedilol, fluoxetine, paroxetine, venlafaxine, tamoxifen, codeine):** Caution and monitor. Berberine increases the human CYP2D6 dextromethorphan metabolic ratio ninefold ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)), risking beta-blocker bradycardia, antidepressant toxicity, or reduced prodrug activation; consider non-CYP2D6 alternatives or dose titration.  
- **Prescription CYP2C9 substrates (warfarin, losartan, irbesartan, glipizide, celecoxib):** Caution and monitor. Berberine doubles the human CYP2C9 losartan-to-metabolite ratio ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)), risking warfarin bleeding, sulfonylurea (insulin-secreting diabetes drug) hypoglycemia, or attenuated losartan effect; monitor clotting time, glucose, and blood pressure.  
- **Prescription CYP3A4 substrates (simvastatin, atorvastatin, amlodipine, diltiazem, midazolam, apixaban):** Caution and monitor. Berberine raises human midazolam AUC by 40%, whereas CYP1A2 (liver enzyme clearing caffeine) and CYP2C19 (liver enzyme clearing omeprazole) are unaffected ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)); monitor for statin myopathy or hypotension.  
- **Antidiabetic and antihypertensive drugs (metformin, insulin, glimepiride, lisinopril, valsartan):** Monitor (theoretical). Combination trials show glucose and blood-pressure reductions ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/); [Lan et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25498346/)), risking additive hypoglycemia or hypotension; monitor blood glucose and blood pressure and adjust doses.  
- **QT-prolonging medications (azithromycin, ciprofloxacin, amiodarone, sotalol, ondansetron, haloperidol):** Caution (theoretical). High-dose Nexrutine was associated with Grade 1 QTc prolongation in 14.3% of patients ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)), risking additive ventricular arrhythmia; obtain baseline and follow-up electrocardiograms and maintain normal potassium.  
- **Over-the-counter medications (dextromethorphan, ibuprofen, naproxen, diphenhydramine, omeprazole):** Caution. Constituent berberine strongly inhibits dextromethorphan (CYP2D6) and nonsteroidal anti-inflammatory drug (NSAID, pain and inflammation relievers like ibuprofen and naproxen via CYP2C9) clearance while sparing omeprazole (CYP2C19) ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)); avoid concurrent high-dose dextromethorphan.  
- **Berberine-containing and metabolic/sedative supplements (berberine, goldenseal, Oregon grape, *Coptis chinensis*, ashwagandha, valerian, alpha-lipoic acid):** Avoid stacking berberine-rich herbs (theoretical) to prevent cumulative CYP450 inhibition and limonoid load ([Fan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31614806/)); monitor glucose and sedation with hypoglycemic or calming botanicals.  
  
**Populations who should avoid Phellodendron amurense:**  
  
- **Pregnant or lactating women, neonates, and G6PD-deficient individuals:** Berberine displaces bilirubin from serum albumin and inhibits hepatic glucuronidation, risking severe neonatal hyperbilirubinemia and kernicterus ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/); [Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)).  
- **Individuals with baseline QTc prolongation or hypokalemia:** High-dose Nexrutine (1,500 mg/day) produced transient Grade 1 QTc prolongation (14.3%) and Grade 3 hypokalemia (4.8%) in clinical testing ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)).  
- **Organ transplant recipients and patients on narrow-therapeutic-index CYP2D6, CYP2C9, or CYP3A4 drugs without drug-level monitoring:** Berberine raises cyclosporine A trough levels by 29.3% over control and inhibits CYP2D6 ninefold ([Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/); [Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)).  
- **Competitive athletes subject to WADA anti-doping testing:** Hepatic metabolism of constituent coclaurine generates urinary higenamine glucuronide, a WADA-prohibited beta-2 agonist at all times ([Sakamoto et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40751788/)).  
- **Individuals with moderate-to-severe renal or hepatic impairment:** High-dose Nexrutine (750 mg/kg/day) caused rat renal tubular degeneration ([Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)) and limonin induces dose-dependent rodent hepatorenal toxicity ([Fan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31614806/)).  
  
  
## Risk Mitigation Strategies  
  
Doses, timings, and monitoring intervals below follow common practice unless cited.  
  
- **Mealtime split dosing:** Administering capsules in divided doses of 250 to 500 mg with meals ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/); [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)) mitigates the nausea, heartburn, and diarrhea reported with concentrated bark extracts.  
- **Pharmacokinetic medication audit:** Screening all prescription and over-the-counter drugs for CYP2D6, CYP2C9, CYP3A4, and P-gp substrates before initiation prevents supratherapeutic drug accumulation and calcineurin-inhibitor toxicity ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/); [Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/)).  
- **Electrocardiogram and potassium screening:** Checking an electrocardiogram and serum potassium at baseline and week 4 on 1,500 mg/day Nexrutine—stopping if QTc exceeds 450 ms or potassium falls below 3.5 mmol/L—mitigates arrhythmia risk ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)).  
- **Hepatorenal ceilings:** Limiting cycles to 8–12 weeks and stopping if alanine aminotransferase (ALT, a liver injury enzyme) exceeds 3× normal or estimated glomerular filtration rate (eGFR, a kidney filtration measure) drops mitigates organ toxicity ([Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)).  
- **Pre-competition washout for tested athletes:** Discontinuing all *Phellodendron*-containing products at least 2 weeks before anti-doping sample collection prevents unintentional WADA violations from coclaurine-derived urinary higenamine ([Sakamoto et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40751788/)).  
  
  
## Therapeutic Protocol  
  
Other protocol parameters without a citation below (such as meal timing, titration steps, and cycling intervals) reflect common practice.  
  
- **Standalone bark extract (Nexrutine regimen):** Administered orally at 500 mg three times daily with meals (1,500 mg/day) for 1 to 2 months before and during prostate radiation or surgery, as studied by Gregory Swanson's group ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)).  
- ***Magnolia* & *Phellodendron* blend (Relora):** Dosed at 250 mg twice daily (500 mg/day) for 4 weeks ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)) or 250 mg three times daily (750 mg/day) for 6 weeks ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/); [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/)).  
- ***Phellodendron* & *Citrus sinensis* blend (NP 06-1 joint/metabolic regimen):** Administered orally as two 370 mg capsules twice daily (1,480 mg/day) for 8 weeks, as tested by Julius Oben's group ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/); [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)).  
- **Traditional & topical regimens:** Traditional practice decocts 3–12 g/day of *Guan Huang Bai* bark ([Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)), while topical compound fluid compresses are applied once or twice daily for 5–28 days ([Wan, 2018](https://pubmed.ncbi.nlm.nih.gov/29735457/); [Liu et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32817595/)).  
- **Human half-life & split dosing:** Because berberine and palmatine have a 3-to-5-hour human elimination half-life and < 1% oral bioavailability ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)), protocols split intake into two or three mealtime doses rather than a single daily dose.  
- **Best time of day:** Mealtime dosing (breakfast, lunch, and dinner) aligns with postprandial glucose excursions ([Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/)) and minimizes gastric irritation, while evening Relora doses target nighttime cortisol elevation ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/)).  
- **Genetic polymorphisms:** Known *CYP2D6* or *CYP2C9* poor metabolizers face compounded enzyme blockade from protoberberine alkaloids ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)), favoring lower starting doses (250–500 mg/day) or non-berberine alternatives.  
- **Sex-based differences:** Dosing in clinical trials has not differed between men and women (500–1,500 mg/day across sexes), though premenopausal women were the sole cohort in the 750 mg/day Relora stress-eating trials ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/); [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/)).  
- **Age-related considerations:** In adults over 65, starting at a single 250 to 500 mg/day dose and titrating over 1 to 2 weeks accounts for age-related reductions in hepatic CYP450 clearance and renal tubular reserve.  
- **Baseline biomarker levels:** Protocols targeting glucose or CRP apply primarily when baseline BMI exceeds 25 kg/m², as normal-weight cohorts showed no fasting glucose or CRP change on NP 06-1 ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/); [Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)).  
- **Pre-existing health conditions:** Individuals on chronic CYP450-metabolized medications or with borderline renal/hepatic function require medical supervision or alternative single-ingredient interventions before adopting high-dose bark extracts ([Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/); [Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)).  
  
  
## Discontinuation & Cycling  
  
- **Short-term vs. lifelong use:** Oral *Phellodendron amurense* preparations have only been tested in 4-to-24-week human trials ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/); [Gong et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34532267/)) and are used as short-term courses rather than lifelong daily supplements.  
- **Withdrawal effects:** No physiological dependence, rebound cortisol elevation, or withdrawal syndrome has been reported upon stopping Relora, NP 06-1, or Nexrutine in clinical studies ([Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/); [Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)).  
- **Tapering-off protocol:** Abrupt discontinuation is well tolerated; when used in *Magnolia*-containing blends (Relora) for perceived stress or sleep quality, stepping down from two or three capsules to one evening capsule over 5 to 7 days is common practice.  
- **Cycling for efficacy and safety:** Periodic cycling—8 to 12 weeks on followed by 2 to 4 weeks off—allows hepatic CYP450 enzymes to recover ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)) and limits cumulative renal limonoid exposure ([Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)).  
  
  
## Sourcing and Quality  
  
- **Species authentication (*Guan Huang Bai* vs. *Chuan Huang Bai*):** Commercial products labeled simply "Phellodendron" or "Huang Bai" frequently substitute *Phellodendron chinense*, which contains 3.0%–8.0% berberine versus 0.6%–4.5% in *Phellodendron amurense* ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/); [Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)), altering drug-interaction potency.  
- **Formulation and standardization transparency:** Quality supplements specify *Phellodendron amurense* inner bark and marker percentages—such as ≥ 0.6% berberine and ≥ 0.3% palmatine in pharmacopeial bark ([Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)) or ≥ 1.5% honokiol and ≥ 0.1% berberine in Relora.  
- **Third-party contaminant testing:** Bark harvested in industrial regions can accumulate heavy metals, mycotoxins, and pesticides; verify International Organization for Standardization (ISO, global technical standards body)-17025 lab certificates and note coclaurine-to-higenamine conversion ([Sakamoto et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40751788/)).  
- **Reputable brands:** Next Pharmaceuticals produces patented **Relora** (encapsulated by **NOW Foods** and **Thorne**) and **Nexrutine**; **Life Extension** offers standardized bark formulas, while **Treasure of the East** and **KPC Herbs** supply authenticated *Guan Huang Bai* granules.  
  
  
## Practical Considerations  
  
- **Time to effect:** Postprandial glucose attenuation appeared within 15–75 minutes in acute testing ([Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/)), cortisol and mood shifts emerged at 4–6 weeks ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)), and joint pain and lipid changes required 8 weeks ([Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)).  
- **Common pitfalls:** Consumers frequently mistake whole *Phellodendron amurense* bark (0.6%–4.5% berberine) for high-dose purified berberine hydrochloride (900–1,500 mg/day in [Lan et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25498346/)), overlook CYP2D6/CYP2C9/CYP3A4 medication interactions ([Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/)), or purchase unauthenticated *Huang Bai* powders.  
- **Regulatory status:** In the United States, *Phellodendron amurense* is marketed as a dietary supplement ingredient without premarket efficacy approval, whereas in China it is regulated as an official pharmacopeial crude drug (*Phellodendri amurensis Cortex*) ([Li et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42075995/)).  
- **Cost and accessibility:** Standardized Relora blends and generic phellodendron capsules are widely accessible online at $12 to $30 per month, whereas standalone clinical-grade **Nexrutine** is periodically harder to source in retail channels.  
  
  
## Interaction with Foundational Habits  
  
- **Sleep:** Potentiating (indirect). Adding *Phellodendron* Bawei tablets to standard care improved Athens Insomnia Scale sleep quality in men with nocturia ([Gong et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34532267/)), and Relora reduced evening cortisol and fatigue ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)). Take the final dose with dinner rather than late at night if gastric reflux occurs.  
- **Nutrition:** Potentiating (direct). Taking *Phellodendron* bark extracts 15 minutes before or with carbohydrate-containing meals blunts postprandial glucose excursions via AMPK activation and intestinal alpha-glucosidase (a carbohydrate-digesting enzyme) inhibition ([Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/)) while buffering bitter-alkaloid stomach irritation. Avoid concurrent grapefruit juice, which compounds intestinal CYP3A4 inhibition.  
- **Exercise:** Mixed—potentiating for acute glucose disposal in [Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/) and overlapping with aerobic exercise for tumor and muscle protection in TRAMP mice ([Patel et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31856170/); [Patel et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31456341/)), but theoretically blunting for mitochondrial hypertrophy adaptations via AMPK activation; separate dosing from resistance workouts by 3–4 hours.  
- **Stress management:** Potentiating (indirect) when combined with *Magnolia officinalis* in Relora, which dampens hypothalamic-pituitary-adrenal (HPA, the brain-adrenal hormone system governing stress responses) axis reactivity and lowers salivary cortisol by 18% over 4 weeks ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)), complementing mindfulness or breathwork practices.  
  
  
## Monitoring Protocol & Defining Success  
  
Before initiating oral *Phellodendron amurense* supplementation—particularly at doses of 750 to 1,500 mg/day or alongside chronic medications—baseline testing establishes organ safety and metabolic or inflammatory starting points. Baseline labs include a comprehensive metabolic panel covering fasting glucose, serum potassium, serum creatinine, eGFR, ALT, aspartate aminotransferase (AST, a liver and muscle enzyme measured to detect tissue injury), and total bilirubin, paired with a fasting lipid panel, high-sensitivity CRP, and a 12-lead electrocardiogram if taking 1,500 mg/day Nexrutine or QTc-prolonging drugs ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/); [Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/)). Ongoing monitoring is performed at 4 weeks (to verify stable potassium, QTc, and liver/kidney markers), at 8 to 12 weeks (to evaluate target lipid, glucose, CRP, or salivary cortisol response and decide whether to continue or discontinue), and every 3 to 6 months during extended cyclical use.  
  
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |  
| --- | --- | --- | --- |  
| Fasting plasma glucose | 70–99 mg/dL (standard reference range) | Efficacy marker: expected to decrease in overweight or insulin-resistant users ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/)). | Draw after a 10–12 hour overnight fast; pair with HbA1c if tracking 12-week glycemic control. |  
| LDL-C & fasting triglycerides | LDL-C < 100 mg/dL; triglycerides < 150 mg/dL (standard reference range) | Efficacy marker: both decreased over 8 weeks in NP 06-1 trials ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/)). | Measure after a 10–12 hour fast at baseline and week 8. |  
| High-sensitivity CRP | < 3.0 mg/L (standard reference range) | Efficacy marker: decreased by 49% in overweight osteoarthritis patients on NP 06-1 ([Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)). | Avoid testing within 2 weeks of an acute viral illness or intense unaccustomed exercise. |  
| Diurnal salivary cortisol | No established target; track percent reduction from individual baseline ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)). | Efficacy marker: composite morning, noon, and evening salivary cortisol fell 18% on Relora. | Collect waking, noon, and evening saliva samples at identical clock times at baseline and week 4. |  
| Serum ALT, AST & total bilirubin | ALT 7–56 U/L; AST 8–33 U/L; bilirubin 0.1–1.2 mg/dL (standard reference range) | Safety check: detects limonoid hepatotoxicity ([Fan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31614806/)) or berberine bilirubin displacement ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)). | Stop use if ALT or AST exceeds 3× the upper limit of normal or bilirubin rises. |  
| Serum creatinine & eGFR | Creatinine 0.6–1.3 mg/dL; eGFR ≥ 60 mL/min/1.73 m² (standard reference range) | Safety check: monitors for high-dose renal tubular stress seen in rat studies ([Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)). | Check at baseline, week 4, and week 8; hydrate well before blood draw. |  
| Serum potassium & 12-lead electrocardiogram (QTc) | Potassium 3.5–5.0 mmol/L; QTc ≤ 450 ms in men, ≤ 470 ms in women (standard reference range) | Safety check: high-dose Nexrutine caused Grade 1 QTc prolongation (14.3%) and Grade 3 hypokalemia (4.8%) ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)). | Indicated at baseline and week 4 when dosing ≥ 1,500 mg/day or co-administering QT-prolonging drugs. |  
  
- **Perceived stress and mood stability:** Track changes in daily tension, irritability, fatigue, and stress-induced snacking over 4 to 6 weeks using standardized questionnaires such as the Profile of Mood States (POMS, a validated mood rating scale) or Perceived Stress Scale (PSS, a standardized stress appraisal questionnaire) ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/); [Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/)).  
- **Joint comfort and walking mobility:** Monitor knee pain during stair climbing, morning stiffness, and walking distance over 8 weeks using the Lequesne Algofunctional Index ([Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)).  
- **Sleep continuity and nocturia frequency:** Track nighttime awakenings and lower urinary tract storage symptoms using the IPSS and Athens Insomnia Scale ([Gong et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34532267/)).  
- **Gastrointestinal tolerance:** Monitor daily for early warning signs of alkaloid intolerance, including post-meal heartburn, nausea, abdominal cramping, or loose stools ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)).  
  
  
## Emerging Research  
  
- **Oral multi-herb diabetic wound trial ([NCT07258381](https://clinicaltrials.gov/study/NCT07258381)):** Multicenter randomized trial (n = 56, estimated completion December 2027) testing oral Mailuo Shutong Pills (containing *Cortex Phellodendri*) for diabetic wound healing. A positive result would support adjunctive multi-herb vascular wound care, whereas a null result would reinforce limiting *Phellodendron* wound therapy to topical use.  
- **Completed topical herpes zoster trial ([NCT06985589](https://clinicaltrials.gov/study/NCT06985589)):** Phase 4 randomized controlled trial (n = 32, completed August 2024, no results posted) evaluating fire needle therapy plus a *Cortex Phellodendri* compound fluid wet compress for acute herpes zoster pain and lesion crusting.  
- **Completed post-fistulotomy wound trial ([NCT06663527](https://clinicaltrials.gov/study/NCT06663527)):** Single-blind randomized controlled trial (n = 60, completed February 2025, no results posted) evaluating Compound *Phellodendron* Decoction fumigating-washing therapy for wound healing and pain after anal fistulotomy.  
- **Unpublished acute stress Relora trial ([NCT02734251](https://clinicaltrials.gov/study/NCT02734251)):** Double-blind, placebo-controlled crossover trial (n = 36, completed May 2016, no results posted) testing Relora on anxiety, mood, and cognition after acute laboratory stress; over a decade of non-publication raises publication-bias concerns.  
- **Unpublished knee osteoarthritis trial ([NCT00577330](https://clinicaltrials.gov/study/NCT00577330)):** Phase 3 randomized controlled trial (n = 110, estimated completion January 2008, status Unknown, no results posted) evaluating Myalgesin (celery seed, *Boswellia serrata*, and *Phellodendron* extracts) for knee osteoarthritis, highlighting selective non-reporting risks.  
- **Standalone vs. combination attribution trials:** Factorial human RCTs comparing isolated *Phellodendron amurense* against *Citrus sinensis* or *Magnolia officinalis* could strengthen its case if monotherapy reproduces the metabolic and cortisol effects of [Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/), [Canale et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23946660/), and [Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/), or weaken it if co-ingredients drive all benefits.  
- **Future human pharmacokinetic and organ-safety research:** Dose-escalation human trials of whole *Phellodendron amurense* bark extracts measuring liver enzyme inhibition, QTc intervals, and kidney injury markers could weaken the case for supplementation if clinical doses trigger the drug interactions of [Guo et al., 2012](https://pubmed.ncbi.nlm.nih.gov/21870106/) or the renal tubular stress of [Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/).  
  
  
## Conclusion  
  
*Phellodendron amurense* inner bark contains active plant compounds that stimulate cellular energy sensors and dampen inflammatory signaling in laboratory studies, yet direct human evidence for health and longevity optimization remains weak and incomplete. No controlled clinical trial has tested oral Amur cork tree bark on its own. Instead, human data come from multi-ingredient blends paired with magnolia bark, sweet orange peel, or crape myrtle, alongside one small unblinded study in prostate cancer patients and topical wound washes. Furthermore, virtually all positive human trials for stress, body weight, joint comfort, blood sugar, and cholesterol were funded or co-authored by the proprietary ingredient manufacturer Next Pharmaceuticals, and their findings are inconsistent across studies and body-weight groups.  
  
Weighed against these uncertain and confounded benefits, oral Amur cork tree bark carries meaningful medication-interaction and safety risks for proactive adults. Its principal active compound strongly blocks liver enzymes and cellular transport pumps responsible for clearing common prescription and over-the-counter medications, creating a substantial hazard of drug accumulation. High-dose human and animal studies also point to mild heart-rhythm recharging delays, potassium shifts, potential kidney and liver strain from bitter bark compounds, and trace conversion into a sports-prohibited stimulant. While purified berberine or single-ingredient stress and joint extracts have direct human trial data, standalone *Phellodendron amurense* bark remains unvalidated for long-term health and longevity.  
  
**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**  
